Canan Akkus

Dr. Canan Akkus

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kirik
Ali Kirik
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Nizameddin KocaNizameddin Koca
Nizameddin Koca
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SSsibel demiral sezer
sibel demiral sezer
TDTeoman Doğru
Teoman Doğru
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.

15 September 2025 in Medicina
Verified
Journal Article
Open access
PDF file
CACanan Akkus
Canan Akkus
ÖÖÖznur Öner
Öznur Öner
AKAtilla Okan Kilic
Atilla Okan Kilic
CDCevdet Duran
Cevdet Duran
Background and Objectives: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder often associated with metabolic disturbances such as insulin resistance and metabolic syndrome (MetS). Visceral adiposity index (VAI) is a validated marker that reflects visceral fat distribution and cardiometabolic risk. This study aimed to compare VAI levels among different PCOS phenotypes to evaluate cardiometabolic risk across these phenotypes. Materials and Methods: This prospective case–control study included 180 PCOS patients and 51 healthy controls without any metabolic or reproductive issues. Patients were divided into the following subtypes based on the Rotterdam criteria: Phenotype A (n = 96), clinical and/or biochemical hyperandrogenism (HA) + oligo-anovulation (OA) + polycystic ovarian morphology (PCOM); Phenotype B (n = 19), HA + OA; Phenotype C (n = 35), HA + PCOM; and Phenotype D (n = 30), OA + PCOM. VAI was calculated for women using anthropometric and biochemical parameters. Results: In the total PCOS group, VAI levels were significantly higher than in controls (p < 0.001). Phenotypes A and B had higher VAI values than controls and also higher in Phenotype A than in Phenotypes C and D (p = 0.003 and p = 0.001, respectively). While present in 38 patients (21.10%) in the PCOS group, there was no metabolic syndrome (MetS) in controls (p < 0.001). In Phenotypes A, B, and D, while more patients had MetS than controls (p < 0.001, 0.004, and 0.021, respectively), more patients had MetS in Phenotype A compared to Phenotypes C and D (p = 0.003 and p = 0.021, respectively). Given ROC analysis, the VAI cut-off value in predicting MetS in the PCOS group was 1.66 (sensitivity = 94.74% and specificity = 83.10%). Conclusions: PCOS phenotypes characterized by HA and OA, particularly Phenotypes A and B, are associated with higher VAI values and an increased frequency of MetS risk. Early identification of these phenotypes may facilitate the implementation of targeted metabolic risk reduction and early intervention strategies, thereby contributing to the reduction of cardiovascular risk.

1 January 2021 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
HYHakan Yilmaz
Hakan Yilmaz
CACanan Akkus
Canan Akkus
RDRahime Duran
Rahime Duran
SDSuleyman Diker
Suleyman Diker
SCSemih Celik
Semih Celik
CDCevdet Duran
Cevdet Duran
Background:To investigate the levels of neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios in those having a pulmonary embolism (PE) in the course of coronavirus disease 2019 (COVID-19). Methods: The records of those having COVID-19 were retrospectively obtained from the hospital automation system. NLR and PLR were measured with the help of patients' blood cell counts. Results: Of 1,452 COVID-19 patients, 17 (1.2%) were diagnosed with PE. Compared with the controls, while leukocyte (p = 0.001), neutrophil (p <0.001), and neutrophil (p = 0.001) percentages, and NLR (p <0.001) and PLR (p = 0.006) had higher values, lymphocyte count (p = 0.004) and lymphocyte percentage (p <0.001) showed lower values in the patients with PE. Compared to the survivors, the non-survivors were found to have increased leukocyte (p <0.001), neutrophil (p <0.001), and neutrophil percentages (p <0.001), NLR (p <0.001) and PLR (p <0.001), and decreased lymphocyte (p <0.001) counts and percentage (p <0.001), hemoglobin (p = 0.005), hematocrit (p = 0.012), and platelet counts (p <0.001). While NLR and PLR cutoffs were found as 4.338 and 187.83 in predicting PE, the cutoff values of NLR and PLR were, respectively, 4.301 and 172.5 in predicting mortality. The logistic regression analysis also revealed that all hematological parameters had no effects on the development of PE. Conclusion: Although NLR and PLR had higher scores in PE patients, no relationship was determined between the levels of NLR and PLR and PE development. Further prospective studies including larger populations are required to enlighten the increased NLR and PLR in PE patients having COVID-19.

31 January 2026 in Indian Journal of Medical Research
Verified
Journal Article
Open access
CACanan Akkus
Canan Akkus
OOOznur Oner
Oznur Oner
AKAtilla Okan Kilic
Atilla Okan Kilic
MTMerve Ucar Toros
Merve Ucar Toros
CDCevdet Duran
Cevdet Duran
Background & objectives: Polycystic ovary syndrome (PCOS) is a common endocrinopathy in reproductive-aged women, frequently associated with insulin resistance, obesity, and increased cardiovascular risk. Serum uric acid, linked to oxidative stress and endothelial dysfunction, may contribute to the cardiometabolic complications of PCOS. Although hyperuricemia is common in PCOS, differences in serum uric acid among phenotypes remain unclear. This study compared serum uric acid across PCOS phenotypes, hypothesising that classic, obese phenotypes would exhibit higher levels due to synergistic metabolic and hormonal effects. Methods: A total of 180 women with PCOS [phenotypes A(n=96), B (n=19), C (n=35), and D (n=30)] and 51 age-matched controls were included. PCOS was diagnosed according to the revised 2003 Rotterdam criteria, and phenotyping was based on the presence of hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology. Fasting serum uric acid levels were measured using the uricase method, and hyperuricemia was detected as ≥6.0 mg/dL. Analyses were performed using the Shapiro–Wilk test for normality, Levene’s test for homogeneity, and appropriate parametric or non-parametric tests with Holm correction for multiple comparisons. Results: Among 231 women evaluated, age distributions were similar between groups. Median body mass index (BMI) and waist circumference (WC) were higher in the PCOS cohort, most prominently in Phenotype A (both P <0.001). Serum uric acid was significantly higher in Phenotype A [4.8 (2.7–8.9) mg/dL] than in controls [4.1 (2.7–6.3) mg/dL] and Phenotype C [4.2 (2.6–5.8) mg/dL] (both P <0.001). Hyperuricemia was more frequent in PCOS than in controls ( P =0.035), occurring predominantly in Phenotype A. Most hyperuricemic patients were obese; notably, no obese controls were available for comparison. Serum uric acid levels were positively associated with BMI (Spearman rho=0.452, + ) and WC (0.412, P <0.001), yet in BMI categories, no significant differences were found in serum uric acid among phenotypes. Interpretation & conclusions: Among PCOS patients, elevated serum uric acid is significantly associated with the classic hyperandrogenic phenotype (Phenotype A) and may also be related to obesity, emphasising the importance of monitoring serum uric acid in obese classical PCOS females, particularly those presenting with Phenotype A.

18 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CACanan Akkus
Canan Akkus
ÖÖÖznur Öner
Öznur Öner
AKAtilla Okan Kilic
Atilla Okan Kilic
CDCevdet Duran
Cevdet Duran
Background and Objectives: We aimed to compare visceral adiposity index (VAI) levels among polycystic ovary syndrome (PCOS) subtypes in this study. Matherials and Methods: A total of 180 PCOS patients and 51 controls were included. Patients were divided into the following subtypes: Phenotype A (n=96), clinical and/or biochemical hyperandrogenism (HA)+oligo-anovulation (OA)+polycystic ovarian morphology (PCOM); Phenotype B (n=19), HA+OA; Phenotype C (n=35), HA+PCOM; and, Phenotype D (n=30), OA+PCOM. VAI was calculated for women by the following formula: (Waist circumference/[36.58+(1.89xBody mass index)])x[(triglyceride(mmol/L)/0.81)x(1.52xHigh density lipoprotein-cholesterol(mmol/L))]. Results: In the total PCOS patients, VAI levels were higher than controls [1.21 (0.39-10.89) and 0.85 (0.32-1.87), respectively] (p< 0.001). VAI levels were higher in Phenotype A [1.46 (0.39-10.89)] and Phenotype B [1.31 (0.43-4.39)] than in controls [0.85 (0.32-1.87)], and also higher in Phenotype A than in Phenotype C [1.00 (0.41-4.79)] and Phenotype D [1.01 (0.4-3.21)] (p=0.003 and p=0.001, respectively). While present in 38 patients (21.1%) in the PCOS group, there was no metabolic syndrome (MetS) in controls (p< 0.001). In Phenotypes A, B, and D, while more patients had MetS than controls (p< 0.001, 0.004, and 0.021, respectively), more patients had MetS in Phenotype A, compared to Phenotypes C and D (p=0.003 and p=0.021, respectively). Given ROC analysis, the VAI cut-off value in predicting MetS in the PCOS group was 1.66 (sensitivity: 94.74% and specificity: 83.1%). Conclusions: PCOS phenotypes characterized by HA and OA, particularly Phenotypes A and B, are associated with higher VAI values and an increased frequency of MetS, underscoring the importance of early metabolic assessment in these patient groups.

13 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ÖÖÖznur Öner
Öznur Öner
CACanan Akkus
Canan Akkus
DDDoga Demircioglu
Doga Demircioglu
IKilhan karanlık
ilhan karanlık
CDCevdet Duran
Cevdet Duran
Background/Aim: Albuminuria is an established marker of endothelial dysfunction and an independent predictor of cardiovascular risk. Polycystic ovary syndrome (PCOS) is associated with early metabolic and vascular abnormalities; however, whether urinary albumin excretion differs across PCOS phenotypes remains unclear. This study aimed to evaluate urinary albumin excretion using the urinary albumin-to-creatinine ratio (U-ACR) across distinct PCOS phenotypes and to examine its association with metabolic parameters. Materials and Methods: In this cross-sectional study, 180 women aged 18-35 years with PCOS and 51 age-matched healthy controls were included. PCOS phenotypes were classified according to the Rotterdam criteria as Phenotype A (n = 96), Phenotype B (n = 19), Phenotype C (n = 35), and Phenotype D (n = 30). Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR). Urinary albumin and creatinine levels were measured in morning urine samples, and U-ACR was calculated. Results: Age was comparable across all groups. Body mass index, waist circumference, diastolic blood pressure, and HOMA-IR were significantly higher in Phenotype A compared with controls and other phenotypes, indicating a more adverse metabolic profile. Serum creatinine levels were similar across all groups. Despite this unfavorable metabolic profile in Phenotype A, U-ACR was significantly elevated only in Phenotype B compared with controls (p = 0.018) and Phenotype D (p = 0.016). No significant correlations were observed between U-ACR and age, body mass index, or HOMA-IR. When participants were categorized according to U-ACR levels (< 30, 30-299.9, and ≥ 300 mg/g creatinine), no significant differences in category distribution were observed between the total PCOS cohort, phenotype subgroups, and controls. Conclusion: Among PCOS phenotypes, U-ACR elevation was observed exclusively in Phenotype B despite similar renal function markers. Notably, this occurred even though Phenotype A exhibited a more adverse metabolic profile, suggesting a dissociation between metabolic burden and early microvascular involvement across PCOS phenotypes. These findings indicate that vascular risk in PCOS may be phenotype-dependent and support the potential value of phenotype-oriented cardiovascular risk assessment.